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Dominant cytotoxic NK cell subset within
CLPD-NK patients identiﬁes a more
aggressive NK cell proliferation
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Samuela Carraro1, Matteo Leoncin1,2, Cristina Vicenzetto1,2, Anna Cabrelle2, Monica Facco1,2, Francesco Piazza1,2,
Gianpietro Semenzato1,2 and Renato Zambello1,2
Natural killer (NK) cells represent a class of innate
lymphocytes with large granular morphology and cyto-
toxic functions, characterized by the CD3–/CD16+/CD56
+ phenotype. According to CD56 expression, two major
NK cell subsets can be recognized, CD56high/CD16dim/neg
NK cells with the ability to release cytokines and
CD56dim/CD16high NK cells displaying cytotoxic ability
toward virus infected or neoplastic cells1. NK cells are
traditionally considered part of innate immunity but evi-
dence has been recently provided that a distinct NK cell
subset may respond to speciﬁc antigens like adaptive
immune cells2. These NK cells, also known as “NK
memory”, are induced by the chronic stimulation of viral
infections or by cytokines (IL-12, IL-15 and IL-18) and are
included in the CD56dim/CD16high NK cells subgroup
equipped with CD57 but lacking CD62L2,3. Chronic
lymphoproliferative disorder of NK cells (CLPD-NK) is a
provisional entity, recognized by the 2016 WHO classiﬁ-
cation, characterized by chronic expansion of at least 500/
mm3 NK cells with restricted killer immunoglobulin-like
receptor (KIR) pattern, whose assessment is of crucial
relevance due to the lack of T-cell receptor rearrangement
in NK cells4,5. CLPD-NK has generally an indolent course,
most patients being asymptomatic and the main feature of
the disease being represented by the development of
neutropenia4. Only few data are available on the patho-
genesis of this indolent disorder but a constitutive acti-
vation of anti-apoptotic signaling pathways is likely to play
a relevant role5. The discovery in 2012 of somatic STAT3
mutations, in about 40% of T-cell large granular lym-
phocyte leukemia (T-LGLL) and in about 30% of CLPD-
NK, focused the attention on a constitutive activation of
Janus Kinase-Signal Transducers and Activators of
Transcription (JAK-STAT) pathway in the development
of this disorder6,7. In addition, somatic STAT5bmutations
were recently recognized in rare aggressive variants of
LGLL and indolent CD4+ T-LGLL8.
This rare disorder remains an extremely heterogeneous
disease, some patients being completely asymptomatic,
whereas others require speciﬁc treatment. For this reason,
using ﬂow cytometry and regardless of KIR expression,
the aim of this study was to identify different biological
and clinical CLPD-NK patients’ subsets. By ﬂow analysis,
NK cells of 25 patients affected by CLPD-NK were ana-
lyzed for CD16 and CD56 expression (Supplementary
Methods), recognizing two major NK cell subsets, that is,
patients with CD56dim/CD16dim NK cells (4/25, 16%) and
patients with CD56neg/dim/CD16high NK cells (21/25, 84%)
(Figs. 1a–c). All patients were evaluated for clinical and
hematological characteristics. Median age was 62 years
(range 42–79) with no signiﬁcant difference between
CD56dim/CD16dim and CD56neg/dim/CD16high subgroups.
As expected, neutropenia (absolute neutrophil count
(ANC) < 1500/mm3) was the most relevant feature,
detected in 10 out of 25 patients (40%), with 5 patients
(20%) presenting severe neutropenia (ANC < 500/mm3).
Anemia and thrombocytopenia have been detected only
in a minority of patients (2/25 and 3/25, respectively) and
were generally mild (Table 1). In terms of clinical pre-
sentation, almost all symptomatic patients were included
in the CD56neg/dim/CD16high subgroup with 8 out of 21
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(38%) patients presenting neutropenia and 5 out 21 (24%)
severe neutropenia. Only three patients required
treatment (low-dose cyclophosphamide in two cases
and methotrexate in one) during the natural history
of the disease, all belonging to CD56neg/dim/CD16high
subset.
Considering the clinical heterogeneity of CD56neg/dim/
CD16high subset, we analyzed the expression of CD57 on
Fig. 1 (See legend on next page.)
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cells of these patients identifying a 51 ± 13.5% mean
expression positivity. Of notice, all ﬁve patients who
experienced severe neutropenia and all symptomatic
patients requiring treatment presented a signiﬁcantly
lower CD57 mean expression toward other CD56neg/dim/
CD16high patients (12.48% ± 2.87 vs 60.43% ± 4.38, p <
0.0001, Fig. 1d). As a consequence CD57–/CD57+ ratio
was signiﬁcantly higher in symptomatic patients as com-
pared with remnant CD56neg/dim/CD16high patients
(10.84 ± 5.24 vs 0.84 ± 0.33, p= 0.0007, Fig. 1e). Taken
these data together, through immunophenotype, three
major NK cell subgroups of patients can be identiﬁed.
CD16 levels discriminated between CD56dim/CD16dim
subgroup and CD56neg/dim/CD16high subgroup. Among
the latest, CD57 expression identiﬁed patients who
experienced severe neutropenia characterized by a
“Cytotoxic” phenotype with CD57 negativity from less
symptomatic patients characterized by CD57 expression,
resembling the “NK Memory” phenotype (Figs. 1f, g,
respectively). All the three subgroups displayed high
CD94 expression, whereas only CD56dim/CD16dim NK
cells expressed discrete amount of CD62L. No statistically
signiﬁcant differences in CD94-NKG2A/C and KIR
expression were found among the three subgroups
although CD94/NKG2C phenotype and KIR restriction
for CD158b and CD158e were almost exclusively distinct
features of NK “Memory” subgroup (8/16 and 3/16,
respectively), whereas CD56dim/CD16dim and NK “Cyto-
toxic” subgroups displayed CD94-NKG2A phenotype and
presented a skewed KIR pattern characterized by lack
of KIR expression (3/4 and 5/5, respectively). All these
features are reported in Table 1.
STAT3 exon 21 mutations analysis and STAT5b
exons 16 to 18 analysis were performed in our cohort
of patients (Supplementary Methods). As previously
reported9, the frequency of STAT3 mutated patients
was lower with respect to T-LGLL with only two (8%)
mutated patients found. These latters were characterized
by the “Cytotoxic” NK immunophenotypic signature
without dominant KIR expression and NKG2A pattern.
In addition, all mutated patients presented severe
neutropenia and required treatment during the
natural history of the disease. None STAT5b mutated
patient was found in our cohort of CLPD-NK patients
(Table 1).
With the aim of identifying biological features matching
with clinical characteristics, we focused on the recogni-
tion of a speciﬁc NK cell immunophenotypic signature
that eventually allows a biological and clinical classiﬁca-
tion of this rare disorder. We found that, independently
from KIR expression, patients characterized by CD56neg/
dim/CD16high/CD57- cytotoxic NK cell expansion repre-
sent a different phenotypic subgroup characterized by
symptomatic disease and by the presence of STAT3
mutation, suggesting a more aggressive NK cell pro-
liferation. These ﬁndings agree with the article of Morice
et al.10 in which CLPD-NK patients were classiﬁed upon
CD56 expression; CD56neg NK cell patients were
Fig. 1 Immunophenotypic features of CLPD-NK patients and their correlation with neutrophil count. a–c Immunophenotypic analysis of NK
cells. CD3+ lymphocytes were excluded from the analysis (panel a, green). CD3- lymphocytes (panel a, blue) were studied for CD56 and CD16
relative expression identifying CD56high/CD16dim/neg NK cells (pink), CD56dim/CD16dim NK cells (gray) and CD56dim/neg/CD16high NK cells (blue). As a
consequence, patients were classiﬁed according to the predominant NK cell subset, of notice CD56dim/CD16dim NK cell subgroup (panel b) and
CD56dim/neg/CD16high NK cell subgroup (panel c). d, e Dot plot indicating differential CD57 expression (%) in CD56dim/neg/CD16high subgroup
between patients who experienced severe neutropenia (ANC < 500/mm3) and patients who did not (ANC > 500/mm3). As represented, patients with
ANC < 500/mm3 presented CD57% expression signiﬁcantly lower (p < 0.0001) toward patients with ANC > 500/mm3 (panel d). As a consequence,
patients who experienced severe neutropenia presented a CD57–/CD57+ mean ratio signiﬁcantly higher towards patients who did not (p= 0.0007;
panel e). f, g Immunophenotypic analysis for CD57 and CD62L among CD56dim/neg/CD16high NK cells (blue). CD57 expression (orange) discriminates
two patient’s subgroups characterized by CD57 negativity (panel f) and positivity (panel g) respectively, which we identify as “Cytotoxic” and
“Memory” NK subgroups. As previously demonstrated, no signiﬁcant CD62L expression was found, conﬁrming that both subsets are constituted by
terminal differentiated NK cells
Table 1 Clinical features of CLPD-NK patients
CD56dim/
CD16dim
(n= 4)
CD56dim/neg/
CD16high/CD57
+ NK
“Memory” (n=
16)
CD56dim/neg/
CD16high/CD57-
NK “Cytotoxic”
(n= 5)
CD94/NKG2A 4/4 (100%) 13/16 (81%) 5/5 (100%)
CD94/NKG2C 1/4 (25%) 4/16 (25%) 0/5
CD158a 1/4 (25%) 0/16 0/5
CD158b 0/4 8/16 (50%) 0/5
CD158e 0/4 3/16 (19%) 0/5
Neutropenia 2/4 (50%) 3/16 (19%) 5/5 (100%)
Severe neutropenia 0/4 0/16 5/5 (100%)
Treatment 0/4 0/16 3/5 (60%)
Anemia 0/4 0/16 2/5 (40%)
Thrombocytopenia 0/4 2/16 (13%) 1/5 (20%)
STAT3 mutation 0/4 0/16 2/5 (40%)
STAT5b mutation 0/4 0/16 0/5
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characterized by CD16 expression, presence of cytopenia
and treatment requirement. However, this analysis alone
may not be enough considering that also among CD56neg/
dim/CD16high patients, a different clinical behavior can be
recognized. We found that patients who experience severe
neutropenia and eventually require treatment belong to
the CD56neg/dim/CD16high/CD57– NK subset, thus con-
ferring a prognostic role to CD57. As a further con-
ﬁrmation, the speciﬁc CD56neg/dim/CD16high/CD57–
immunophenotypic signature is also partially associated
to a speciﬁc biological hallmark of LGL leukemia, which is
the presence of STAT3 mutation. As we recently
demonstrated in T-LGLL11, also in this large cohort of
CLPD-NK patients, immunophenotypical analysis can
identify patients with symptomatic disease and might
represent a suitable surrogate of STAT3 mutation
sequencing. WHO 2016 classiﬁcation conﬁrmed CPLD-
NK as a provisional entity, emphasizing the high hetero-
geneity of the disease4,7,12. The frequency of STAT3
mutated patients found in our cohort is slightly lower as
compared with what has been reported in previous studies
by Jerez and Rajala7,12. This feature can be explained by a
higher frequency of symptomatic and treated patients in
their study populations, possibly due to enrichment in NK
“Cytotoxic” patients, as herein deﬁned. Unfortunately, in
the above articles7,12, the frequency of CD57 NK cells was
not reported.
Clonality assessment for NK cell neoplasms still repre-
sents an Achilles heel due to the lack of a clonotypic
structure on these cells. Besides, only a small fraction of
CLPD-NK reveals STAT3 mutation, the majority of
patients displaying wild-type STAT3. For this reason,
other biological features were assessed to prove the clonal
proliferation. Historically, a skewed pattern of KIR
expression was considered as a reliable surrogate of
clonality to characterize pathological NK cell expan-
sion13,14. On the contrary, Bàrcena and colleagues9, using
HUMARA assay to distinguish monoclonal vs polyclonal
proliferation, recognized a surrogate for NK clonality in
CD94high/HLA-DR+ signature. This approach was able to
identify a concordance between the presence of STAT3
mutation and monoclonal NK cell proliferation but, sur-
prisingly, not signiﬁcant differences were found between
monoclonal and polyclonal patients in terms of clinical
features (speciﬁcally the presence of cytopenia), suggest-
ing that a percentage of truly CLPD-NK symptomatic
patients were missed by this classiﬁcation. In addition,
CD94 expression represents a speciﬁc marker of mature
NK cells that is not suitable for distinction between
polyclonal and monoclonal NK cell proliferations.
The etiology of LGLL is still unknown but several
authors hypothesized that chronic antigenic stimulation
can trigger an initial LGL proliferation that subsequently
carries on as a consequence of persistent cytokine
stimulation or gain of somatic mutation (i.e., STAT3
mutation)5. The evidence that some patients are char-
acterized by NK cells expansion with memory-like phe-
notype, may support this hypothesis. In fact, several
studies highlighted that viral stimulation by cytomegalo-
virus can trigger a CD57+/NKG2C NK cell expansion
with memory properties and, in some cases, this process is
stimulated by cytokines, like IL-12, IL-15 and IL-18,
which have been proven to play a pathogenetic role
in LGLL15.
In conclusion, through NK cell subsets ﬂow analysis,
discrete subtypes of CLPD-NK can be identiﬁed. At var-
iance with KIR expression, which does not correlate with
clinical features, patients characterized by CD56neg/dim/
CD16high/CD57– cytotoxic NK cells expansion represent
a unique phenotypic subgroup characterized by more
symptomatic disease and the presence of STAT3 muta-
tion, suggesting a more aggressive proliferation of
NK cells.
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